核心财务表现 - 2025年第二季度GAAP收入达3.494亿美元 超出市场共识的3.465亿美元 同比增长21.8% [1][2] - 非GAAP每股收益1.49美元 高于市场预期的1.47美元 同比增长10.4% [1][2] - 调整后EBITDA为4390万美元 同比增长24.4% 净收入2210万美元同比增长22.1% [2] - 经营活动现金流2250万美元 同比增长19.7% [2] 业务板块表现 - 个人护理业务占总收入77% 同比增长26.5% 有机增长达7.4% [5] - 伊利诺伊州自2025年1月1日起实施5.5%政府授权费率上调 [5] - hospice服务占总收入17.8% 有机增长率达10.0% [6] - hospice日均患者普查数3720人 增长7.0% 每患者日收入184.92美元增长3.0% [6] - 家庭健康业务仅占总收入5.2% 收入1804.8万美元同比小幅下降 有机收入下降6.0% [7] 战略与运营 - 公司通过收购扩张 已完成Gentiva个人护理服务和宾州Helping Hands家庭护理收购 [8] - 截至2025年6月30日 在23个州拥有260个服务点 服务约6.2万名患者 [8] - 正在推广专有护理人员调度应用程序 提高沟通效率和授权工时捕获能力 [8] - 个人护理业务客户数量从37993人降至36049人 但通过提高单客户服务时长和效率维持增长 [5] 行业与市场 - 家庭护理需求保持强劲 政府支付方关系维护是关键成功因素 [4][9] - 主要收入来自医疗补助和医疗保险计划 政府报销费率变化可能影响利润率 [10] - 核心患者群体为老年和双重资格受益人 医疗补助扩张政策变动直接影响有限 [10]

Amedisys (AMED 1.20%), a leading provider of home health, hospice, and high acuity post-acute care services, reported quarterly earnings for the period ending June 30, 2025, on July 29, 2025. The most significant news is that the company outperformed market expectations on both revenue and adjusted profitability, even as merger-related costs weighed on GAAP results. GAAP revenue reached $621.9 million, ahead of the $611.99 million GAAP consensus, and Non-GAAP EPS was $1.54, well over the $1.36 analyst forec ...

Chemed reported second-quarter earnings that fell short of analysts' expectations, causing its share price to tumble. While Chemed grew sales by 4% in Q2, adjusted earnings per share (EPS) declined by a staggering 22%. Meanwhile, management cut 2025 EPS guidance from $25.20 to $22.15, implying a 4% decline from last year's earnings. Adding further uncertainty, the company announced Nick Westfall, CEO of Vitas Healthcare, was stepping down. Chemed missed expectations on both the top and bottom lines with its ...